SAN DIEGO, March 15, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of David L. Lacey, M.D. and Michael Gallatin, Ph.D. to the company's Therapeutic Advisory Board (TAB). Drs. Lacey and Gallatin will join two founding members of AnaptysBio's TAB, Jan de Vries, Ph.D. and Nicholas B. Lydon, Ph.D.
AnaptysBio's TAB is constituted to oversee the company's internal product pipeline, including the identification of antibody targets, selection of lead candidates for preclinical development and design of clinical development strategies. AnaptysBio is currently advancing internal programs across a number of therapeutic areas, including autoimmunity/inflammation, cancer immunotherapy and muscle wasting disorders.
"We are pleased to augment our TAB with the addition of Dr. Lacey and Dr. Gallatin's world-recognized expertise," said Hamza Suria, AnaptysBio's president and chief executive officer. "AnaptysBio will continue to expand its product pipeline with compelling therapeutic antibody candidates generated using our SHM-XEL platform."
Dr. Lacey is a former senior vice president and head of discovery research at Amgen with over 30 years of basic and clinical research experience. Dr. Lacey played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen as well as the development of the anti-RANKL human antibody known as denosumab. He was most recently responsible for leading a group of over 1,200 FTEs in Amgen's discovery research unit across hundreds of preclinical projects in hematology/oncology, inflammation, metabolic disorders and neuroscience. Dr. Lacey received an M.D. from the University of Colorado and was trained in pathology at the Washington University Medical Center, St. Louis, M
|SOURCE AnaptysBio, Inc.|
Copyright©2010 PR Newswire.
All rights reserved